Intercept Announces FDA Acceptance of Supplemental New Drug Application for Ocaliva® (obeticholic acid) for the Treatment of PBC

sNDA intended to satisfy post-marketing requirements to confirm a clinical benefit in patients with PBCPrecedent-setting submission includes data from post-marketing studies COBALT and Study 401 as...

Related Keywords

Paul Nitschmann ,Advisory Committee ,Linkedin ,Regulatory Affairs At Intercept ,Drug Administration ,Globenewswire Inc ,Twitter ,International Normalized Ratio ,Intercept Pharmaceuticals Inc ,New Drug Application ,Prescription Drug User Fee Act ,Senior Vice President ,Regulatory Affairs ,Narrow Therapeutic ,Bile Salt Efflux ,Full Prescribing Information ,Intercept Pharmaceuticals ,